VRP.L

Verona Pharma Plc
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
22nd October 2020, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its unaudited financial results for the three and nine months ended September 30, 2020 on Thursday, October 29, 2020 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 2469127:

  • +1-888-317-6003 for callers in the United States
  • +1-412-317-6061 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will be available there for 90 days.

For further information, please contact:

  
Verona Pharma plcTel: +44 (0)20 3283 4200
Victoria Stewart, Director of Communicationsinfo@veronapharma.com
  
N+1 Singer
(Nominated Adviser and UK Broker)		Tel: +44 (0)20 7496 3000
Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance) 
Tom Salvesen (Corporate Broking) 
  
Optimum Strategic Communications
(European Media and Investor Enquiries)		Tel: +44 (0)203 950 9144
verona@optimumcomms.com
Mary Clark / Eva Haas / Shabnam Bashir 
  
Argot Partners
(U.S. Investor Enquiries)		Tel: +1 212-600-1902
verona@argotpartners.com
Kimberly Minarovich / Michael Barron 

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine is in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

]]>

TwitterFacebookLinkedIn